MedTrace Logo

Antioxidant Therapy to Reduce Inflammation in Sickle Cell Disease

NCT01054768 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 37

Last updated 2021-08-03

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine whether alpha-lipoic acid and acetyl-L-carnitine will lower systemic inflammation in patients with Sickle Cell Disease by reducing oxidative stress, which will result in a decrease in the frequency of vaso-occlusive pain episodes and improve their quality of life.

Conditions

  • Anemia, Sickle Cell

Interventions

DRUG

alpha-lipoic acid and acetyl-L-carnitine

none to report

DRUG

Control

none to report

Sponsors & Collaborators

  • National Center for Complementary and Integrative Health (NCCIH)

    collaborator NIH

  • UCSF Benioff Children's Hospital Oakland

    lead OTHER

Principal Investigators

  • Elliott Vichinsky, M.D. · UCSF Benioff Children's Hospital Oakland

  • Bruce N. Ames, Ph.D. · UCSF Benioff Children's Hospital Oakland

  • Ashutosh Lal, M.D. · UCSF Benioff Children's Hospital Oakland

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
10 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-08-31
Primary Completion
2013-04-30
Completion
2013-04-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01054768 on ClinicalTrials.gov